(S)-(+)-3-Hydroxytetrahydrofuran | CAS:86087-23-2

We serve (S)-(+)-3-Hydroxytetrahydrofuran CAS:86087-23-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(S)-(+)-3-Hydroxytetrahydrofuran

Chemical Name:(S)-(+)-3-Hydroxytetrahydrofuran
CAS.NO:86087-23-2
Synonyms:(S)-TETRAHYDROFURAN-3-OL
(S)-(+)-tetrahyro-3-furanol
Molecular Formula:C4H8O2
Molecular Weight:88.10510
 
Physical and Chemical Properties:
Density:1.298
Melting point:-140ºC
Boiling point:80ºC
Flash point:79ºC
Index of Refraction:1.449-1.451
 
HS Code: 2932190090
UN No.: UN3265
Hazard class: 8 categories 
Packing level: Class III
 
Specification:
Appearance:Yellow to light brown transparent liquid
Purity:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Afatinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.



Contact us for information like (S)-(+)-3-Hydroxytetrahydrofuran chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S)-(+)-tetrahyro-3-furanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(S)-(+)-tetrahyro-3-furanol Use and application,(S)-(+)-tetrahyro-3-furanol technical grade,usp/ep/jp grade.


Related News: Could a traditional Chinese medicine help fight the Wuhan coronavirus, or is one of the country’s most influential state media outlets promoting pseudoscience and false hope?Vitamin A manufacturer Could a traditional Chinese medicine help fight the Wuhan coronavirus, or is one of the country’s most influential state media outlets promoting pseudoscience and false hope?[dimethylamino-(2,5-dioxopyrrolidin-1-yl)oxymethylidene]-dimethylazanium,hexafluorophosphate supplier In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.1-Bromo-2,3-difluorobenzene vendor In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.